Biocon Limited

Centro De Inmunologia Molecular

Centro De Immunologia Molecular

Centro De Inmunologia Molecular (cim)

Biocon Limited & Centro De Immunologia Molecular

Centro De Inmunolgia Molecular

Jose Enrique Montero Casimiro

Ramakrishnan Melarkode

Pradip Nair

Rolando Perez Rodriguez

Laxmi Adhikary

Josefa Lombardero Valladares

Kedarnath Nanjund Sastry

Monalisa Chatterji

Hema Balasubramanian

Sundaraj David Rajkumar

Bala S Manian

Dinesh Baskar

Ankur Bhatnagar

Saravanan Desan

Usha Bughani

Harish Venkatraman Pai

Sunaina Prabhu

Kriti Shukla

Rasika Venkataraman

Abhijit Barve

Agustin Bienvenido Lage Davila

Patricia Sierra Blazquez

Rosa Blanca Tormo Bravo

The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.

Monoclonal antibody and a method thereof

The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.

Use of a CD6 binding partner and method based thereon

The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions.

Methods for controlling fucosylation levels in proteins

The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or a eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions.

The present invention relates to methods of treatment useful in chronic diseases, by means of the rupture of tolerance to self-antigens and increasing autoimmune response against these antigens. More particularly, the present invention relates to methods useful in the treatment of tumors that are growth dependent on the Epidermal Growth Factor, including non-small cell lung carcinoma. In the present invention a therapeutic combination is revealed that includes the combination of a vaccine against self antigens with a monoclonal antibody against peripheral T cells or a chemotherapeutic drug able to induce a depletion of peripheral T cells. In another one of its aspects the present invention reveals a method of treatment of chronic diseases in which the rupture of the tolerance to self antigens is essential for the control of the disease, this method includes the administration of a immune suppressor agent between two cycles of vaccination against a self antigen, which could be for example the EGF, being this scheme of effective treatment for the reduction of tumors whose growth depends on EGF.

Method for the treatment of malignant and infectious chronic diseases

Monoclonal antibodies that recognize the CD6 antigen, pharmaceutical compositions that recognizes and that are able to achieve a clinical and histological effectivity in patients with different clinical types of Psoriasis.

Anti-CD6 monoclonal antibodies and their uses

Growing community of inventors

Habana, Cuba

Jose Enrique Montero Casimiro